Bli medlem
Bli medlem

Du är här

2014-06-11

AstraZeneca: AstraZeneca to present new data from its broad portfolio in wide range of patient populations at the ADA 74th Scientific Sessions®

43 abstracts on approved products and an investigational compound
accepted for presentation

First data from Phase III trial of saxagliptin/dapagliflozin
combination presented as a late-breaker

First six-year, open-extension to the DURATION-1 trial examining the
efficacy and tolerability of exenatide will be presented

AstraZeneca today announced that 43 abstracts reporting results of the
company's research and development in diabetes have been accepted for
presentation at the 74th Scientific Sessions® of the American
Diabetes Association (ADA) in San Francisco, 13-17 June 2014.
Clinical data from studies evaluating multiple approved products,
including Forxiga® (dapagliflozin, marketed in the US as Farxiga™),
Bydureon® (exenatide extended-release for injectable suspension) and
Onglyza® (saxagliptin), as well as the investigational combination of
saxagliptin and dapagliflozin, demonstrate AstraZeneca's continued
commitment to addressing unmet medical needs across a wide spectrum
of type 2 diabetes patients in different stages of the disease.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "The robust
scientific data that will be presented at ADA further strengthen our
broad innovative portfolio that spans the entire spectrum of
non-insulin anti-diabetic treatments. Our continued focus on
advancing scientific knowledge reinforces our long-term commitment to
diabetes, a core strategic area for us and an important platform for
returning AstraZeneca to growth."

"Diabetes is a progressive and complex disease which demands
combination approaches to further improve patient care," said Briggs
Morrison, MD, Executive Vice President, Global Medicines Development
& Chief Medical Officer, AstraZeneca. "Our data accepted for
presentation at this year's ADA, including trials evaluating our
medicines in patients with significant comorbidities and in
combination with other anti-diabetic agents, reflect AstraZeneca's
efforts to provide these treatment options that address the needs of
patients at different stages of the disease."

Notable data on an AstraZeneca investigational compound at ADA
include:

· A late-breaker of the first presentation of Phase III data
evaluating the investigational combination of
saxagliptin/dapagliflozin as a dual add-on therapy in adult patients
with type 2 diabetes who were inadequately controlled on metformin,
the top-line results of which were announced in May
(http://www.astrazeneca.com/Media/Press-releases/Article/20140513--astraz...).
Results being presented at ADA, and published in the abstract
available in Diabetes, include secondary outcome measures on body
weight and efficacy. (#127-LB, Sunday, 15 June, 12:00 PM PDT)[1]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn1)

Notable data on approved AstraZeneca products at ADA include:

· An analysis from nine double-blind, placebo-controlled trials
evaluating the safety of dapagliflozin in elderly patients (#269-OR,
Monday, 16 June, 9:30 AM PDT)[2]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn2)

· An analysis from three randomised controlled trials examining the
effect of exenatide extended-release for injectable suspension on
daily blood glucose variability compared with basal insulin (#997-P,
Saturday, 14 June, 11:30 AM PDT)[3]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn3)

· A sub-group analysis from the SAVOR trial examining the effect of
saxagliptin on renal outcomes (#544-P, Saturday, 14 June, 11:30 AM
PDT)[4]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn4)

· An analysis from two double-blind, placebo-controlled trials
evaluating the effects of dapagliflozin on systolic blood pressure
(#1033-P, Sunday, 15 June, 12:00 PM PDT)[5]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn5)

· A sub-group analysis from the SAVOR trial examining the effect of
saxagliptin in elderly patients from the study population (#1057-P,
Sunday, 15 June, 12:00 PM PDT)[6]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn6)

· An open-ended extension to the DURATION-1 trial examining the
efficacy and tolerability of exenatide once-weekly over six years
(#964-P, Saturday, 14 June, 11:30 AM PDT)[7]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn7)

· An analysis from five placebo-controlled trials examining the
effects of saxagliptin on β-cell function in patients with latent
autoimmune diabetes (#152-OR, Sunday, 15 June, 8:45 AM PDT)[8]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn8)

The complete list of AstraZeneca data presentations can be accessed on
the ADA website here
(http://www.abstractsonline.com/plan/start.aspx?mkey=%7b40FC5C61-819A-4D1...).

- ENDS -

NOTES TO EDITORS

About Type 2 Diabetes

Diabetes is estimated to affect 25.8 million people in the US and more
than 382 million people worldwide. The prevalence of diabetes is
projected to reach more than 592 million people worldwide by 2035.[9]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn9)
Type 2 diabetes accounts for approximately 90-95 percent of all cases
of diagnosed diabetes in adults.[10]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn10)
Type 2 diabetes is a chronic disease[11]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn11)
characterised by pathophysiologic defects leading to elevated glucose
levels.[12]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn12)
Over time, this sustained hyperglycaemia contributes to further
progression of the disease.[13]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn13)
Significant unmet needs still exist, as many adult patients remain
inadequately controlled on their current glucose-lowering
regimen.[14]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_edn14)

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:
www.astrazeneca.com

CONTACTS

Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Vanessa Rhodes +44 20 7604 8037 (UK/Global)

Ayesha Bharmal +44 20 7604 8034 (UK/Global)

Jacob Lund +46 8 553 260 20 (Sweden)

Michele Meixell + 1 302 885 6351 (US)

Investor Enquiries

Karl Hård +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor + 1 302 886 1842 mob: +1 302 357 4882

Anthony Brown +44 20 7604 8067 mob: +44 7585 404943

Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729

----------------------------------------------------------------------

[1]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref1)
Rosenstock, J., et al. "Dual Add-On Therapy in Poorly Controlled Type
2 Diabetes on Metformin: Randomized, Double-Blind Trial of
Saxagliptin+Dapagliflozin vs Saxagliptin and Dapagliflozin Alone."
American Diabetes Association Scientific Sessions 2014. Abstract
#127-LB.

[2]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref2)
Mansfield, T., et al. "Dapagliflozin is Safe and Well-tolerated in
Older patients with T2DM." American Diabetes Association Scientific
Sessions 2014. Abstract #269-OR.

[3]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref3)
Vora, J., et al. "Daily Blood Glucose Variability With Exenatide
Once-Weekly Vs Basal Insulin in 3 RCTs." American Diabetes
Association Scientific Sessions 2014. Abstract #997-P.

[4]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref4)
Mosenzon, O., et al. "Effect of Saxagliptin on Renal Outcomes."
American Diabetes Association Scientific Sessions 2014. Abstract
#544-P.

[5]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref5)
Weber, M., et al. "Dapagliflozin Lowered Ambulatory Blood Pressure in
Patients With T2DM and Hypertension Inadequately Controlled by a
Renin-Angiotensin System Blocker With or Without Another Agent."
American Diabetes Association Scientific Sessions 2014. Abstract
#1033-P.

[6]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref6)
Leiter, L., et al. "Efficacy and Safety of Saxagliptin in Older
Participants in the SAVOR-TIMI 53 Trial." American Diabetes
Association Scientific Sessions 2014. Abstract #1057-P.

[7]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref7)
Henry, R., et al. "An open-ended extension to the DURATION-1 trial
examining the efficacy and tolerability of exenatide once-weekly over
six years." American Diabetes Association Scientific Sessions 2014.
Abstract #964-P.

[8]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref8)
Pozzilli P., et al. "Saxagliptin Increases β-Cell Function and
Improves HOMA Index in Patients with Latent Autoimmune Diabetes in
Adults." American Diabetes Association Scientific Sessions 2014.
Abstract #152-OR.

[9]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref9)
International Diabetes Federation. IDF Diabetes Atlas, 6th edn.,
2013. Available at: http://www.idf.org/diabetesatlas. Accessed April
25, 2014.

[10]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref10)
Centers for Disease Control and Prevention. National Diabetes
Factsheet 2011. Available at:
http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed April
25, 2014.

[11]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref11)
World Health Organization. Media Centre - Diabetes. 2011. Available
at: http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed
April 25, 2014.

[12]
(http://Scripts/lib/tiny_mce_3.4.5/plugins/paste/pasteword.htm#_ednref12)
Kahn SE. The relative contributions of insulin resistance and
beta-cell dysfunction to the pathophysiology of type 2 diabetes.
Diabetologia. 2003;46:3-19.

[13]
(http://Scripts/lib/tiny_mce_3.4....

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.